US FDA Advisory Committee votes to support effectiveness and safety of GSK’s respiratory syncytial virus older adult vaccine candidate
Issued: London, UK
For media and investors only
Committee votes unanimously that the data support the effectiveness of the vaccine, and 10-2 that the data support the safety of the vaccine
FDA decision on US approval expected by 3 May 2023, with...
Zur Pressemeldung auf www.gsk.com